Core A: Administrative and Clinical Translational Core
Core A: Administrative and Clinical Translational Core
批准号:
10713203
负责人:
CARL H. JUNE
金额:
$24.8万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-08-15 至 2028-08-31
关键词:
AchievementAddressAnnual ReportsAuthorization documentationBasic ScienceBiometryBudgetsCAR T cell therapyCancer CenterCellular immunotherapyClinicalClinical DataClinical ProtocolsClinical TrialsCollaborationsCommunicationDataDiseaseDoctor of PhilosophyEnsureGenesGenetic EngineeringGoalsGrantHematologic NeoplasmsHuman ResourcesInfrastructureInstitutionLeadershipLearningLettersMaintenanceMonitorPennsylvaniaPhysician ExecutivesProgress ReportsPublishingRegistered nurseReportingResearchResearch PersonnelRoleSafetyScheduleScientistServicesStructureT cell therapyTechnologyTestingTranslational ResearchUniversitiesUpdateauthoritycancer immunotherapychimeric antigen receptor T cellsclinical developmentclinical research siteclinical translationclinical trial implementationdata managementdata sharingdesigninnovationmedical schoolsmeetingsnoveloperationorganizational structurepharmacovigilancepreclinical developmentpreservationprogramsprotocol developmentresponsesuccesssynergismtimeline
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY CORE A: ADMINISTRATIVE AND CLINICAL TRANSLATIONAL CORE
The Administrative and Clinical Translational Core of this renewal Program Project will provide: (1) scientific
and clinical operational oversight; (2) IND-enabling regulatory and clinical development expertise, and
biostatistical and budgetary structure to support effective operations for each P01 Project and Scientific Core;
and (3) promote project integration and synergy. This renewal proposal seeks to build upon our proven track
record in genetically engineered T cell therapy by enhancing the chimeric antigen receptor T cell platform to
specifically address systemic vulnerabilities that we have observed in our clinical trials to date. Our
overarching hypothesis is that novel gene editing approaches can remove the remaining obstacles in the path
of universally-available and universally-active CAR T cell therapy for hematologic malignancy. We have
brought together a cadre of exceptional investigators who have collaborated and published together for many
years. Each disease-focused project will be led by a recognized authority in the field. The three cores that
support this proposal have been critical to the success of our clinical CAR T cell program to date and their
expertise will underpin the success of this proposal. The centerpiece of each project is an innovative clinical
trial that seeks to test our major hypotheses.
We are leveraging the proven translational infrastructure, administrative staff and the centralized research
organizations at the Center for Cellular Immunotherapies at the Perelman School of Medicine to achieve our
objectives. Strong institutional commitment from the Abramson Cancer Center, Perelman School of Medicine,
the Parker Institute for Cancer Immunotherapy and the University of Pennsylvania have facilitated our
scientific and translational achievements. The essential services provided by Core A include administrative
support for all investigators in each project and core; fiscal management and oversight for all components of
the Program Project; clinical protocol development, IND submissions and maintenance, and clinical data
management; and organization and communication of all Program Project meetings and activities. The overall
goal of this Core is effective and efficient leadership of the P01. The roles of the Director, Co-investigators
and administrative staff are to facilitate communication and organizational structure while stimulating scientific
and technological interactions. In order to achieve this goal, the Core has established four objectives: (1) To
oversee the safety and monitoring activities for Penn and CHOP clinical sites; (2) To provide regulatory,
preclinical development, and statistical support for clinical trials, projects and cores and implement data
sharing plans.; (3) To coordinate the interactions among clinicians and scientists in projects and cores, internal
and external advisory boards, and NCI personnel regarding effective implementation of proposed objective;
(4) To provide budgetary services such as tracking expenses and providing investigator’s monthly reports.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering the Next Generation of T Cells
-
批准号:10578324
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2019
-
负责人:CARL H. JUNE
-
依托单位:
Engineering the next generation of T cells
-
批准号:10064451
-
项目类别:
-
资助金额:$23.31万
-
财政年份:2019
-
负责人:CARL H. JUNE
-
依托单位:
Directing the metabolic fate of CAR T cells
-
批准号:10364746
-
项目类别:
-
资助金额:$42.37万
-
财政年份:2018
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
-
批准号:10713199
-
项目类别:
-
资助金额:$278.23万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
-
批准号:10245064
-
项目类别:
-
资助金额:$31.74万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Biostatistics Core
-
批准号:10245066
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
-
批准号:9982244
-
项目类别:
-
资助金额:$24.16万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:9280418
-
项目类别:
-
资助金额:$289.74万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:10245062
-
项目类别:
-
资助金额:$219.44万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:9982239
-
项目类别:
-
资助金额:$170.2万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Biostatistics Core
-
批准号:9982247
-
项目类别:
-
资助金额:$11.2万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8601689
-
项目类别:
-
资助金额:$48.93万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8889623
-
项目类别:
-
资助金额:$156.67万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8989883
-
项目类别:
-
资助金额:$23.77万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8469110
-
项目类别:
-
资助金额:$128.7万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8243893
-
项目类别:
-
资助金额:$51.14万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8519303
-
项目类别:
-
资助金额:$131.48万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8442843
-
项目类别:
-
资助金额:$47.42万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
FACSAria II Cell Sorter for Non-Biohazardous Cells
-
批准号:7793915
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2010
-
负责人:CARL H. JUNE
-
依托单位:
Core E: Molecular Gene Delivery/Modification Core
-
批准号:8066106
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2010
-
负责人:CARL H. JUNE
-
依托单位:
海外基金